In terms of the concept of 'drug repurposing', we focused on pharmaceutical-grade Bithionol (BT) as a therapeutic agent against ovarian cancer. Our recent in-vitro study provides preclinical data suggesting a potential therapeutic role for BT against recurrent ovarian cancer. BT was shown to cause cell death by caspases-mediated apoptosis. The present preliminary study further explores the antitumor potential of pharmaceutical-grade BT in an in-vivo xenograft model of human ovarian cancer. Nude Foxn1 nu mice bearing SKOV-3 human ovarian tumor xenografts were treated with titrated doses of BT and the therapeutic efficacy of pharmaceutical BT was determined using bioluminescence imaging. BTinduced changes in cell proliferation and apoptosis were evaluated by Ki-67 immunochemical staining and TUNEL assay. The effect of BT on autotaxin levels in serum, ascitic fluid, and tumor tissue was assessed by colorimetric and western blot techniques. BT treatment did not show antitumor potential or enhanced survival time at any of the doses tested. No apparent signs of toxicity were observed with any of the doses tested. Immunohistological analysis of tumor sections did not indicate a significant decrease in cellular proliferation (Ki-67 assay). An increase in apoptosis (by TUNEL assay) was observed in all BT-treated mice compared with vehicle-treated mice. Although BT did not show significant antitumor activity in the present study, the ability of BT to induce apoptosis still makes it a promising therapeutic agent. Further confirmatory and optimization studies are essential to enhance the therapeutic effects of BT.
Introduction
Most epithelial ovarian cancer (EOC) patients are diagnosed at an advanced stage when disease has spread beyond the ovary. The majority of women diagnosed with advanced ovarian cancer have a low overall survival [1] . Although most ovarian cancer patients (70-80%) initially respond to cytoreductive surgery and adjuvant paclitaxel-based and platinum-based chemotherapy, the long-term prognosis is generally poor, with recurrence and development of drug-resistant disease [2, 3] . Therefore, it is essential to explore new agents that can act by novel mechanism(s) of action to improve the overall survival for ovarian cancer patients. New drug discovery requires enormous cost and time. An alternative approach is 'drug repurposing,' wherein clinically approved drugs for one indication are re-explored for new applications. The advantage of 'drug repurposing' is cost and time effectiveness as absorption, distribution, metabolism, excretion, and basic toxicity are already well established and can be immediately taken to phase II/III clinical trials. Keeping this concept in mind, we focused on pharmaceutical-grade Bithionol [2,2′-sulfanediylbis (4,6-dichlorophenol)] (BT), a clinically approved antiparasitic drug, as an antiovarian cancer drug. BT is not commercially available in the USA, but pharmaceuticalgrade BT capsules were obtained from the Centers for Disease Control and Prevention with their approval. The pharmaceutical-grade BT has received Food and Drug Administration approval as a second-line orally administered medication for the treatment of helminthic infection and has been safely dosed in humans [4] .
In our recent in-vitro study, we showed the ability of BT (chemical grade) to exert cytotoxic effects on a panel of ovarian cancer cell lines irrespective of their cisplatin sensitivities [5] . BT was shown to induce cell death by apoptosis and the mechanism(s) of action was shown to be by cell-cycle regulation, reactive oxygen species (ROS) generation, NF-kB inhibition, and autotaxin (ATX) inhibition [5] . To assess whether our in-vitro findings would extend to an in-vivo model, the present study explored the antitumor potential of pharmaceutical-grade BT using a xenograft model of human ovarian cancer in nude mice. As studies on stability, dissolution, best formulation, vehicle, and route of delivery were already established, the major focus of the current study was determination of the optimal dose required for inhibiting the growth of implanted human EOC in nude mice and the effective treatment duration.
In the present study, we established an ovarian cancer xenograft model by an intraperitoneal injection of SKOV-3-luc-D3 human EOC cells into Nude Foxn1 nu mice.
Following tumor establishment, mice were treated with varying doses of pharmaceutical-grade BT. As most ovarian cancer patients are diagnosed at an advanced stage when the disease has spread beyond the ovary [6] , we purposefully delayed BT treatment to mimic the human disease at the detection stage. BT treatment was started at 5 weeks after tumor inoculation to ensure that the majority of mice would show steady and stable tumor burden. Mice that reached predetermined humane or experimental end points were killed as per the Laboratory Animal Care and Use Committee (LACUC) guidelines. Kaplan-Meier survival curves were generated. Following killing, blood and ascitic fluid were collected for ATX measurements. In addition, tumor implants were removed and examined by hematoxylin and eosin (H&E) staining and immunohistochemistry (IHC) for assessment of cell proliferation rate (Ki-67 expression), apoptosis [terminal deoxynucleotide transferase-mediated dUTP nick end labeling (TUNEL)], and ATX status (as a marker of tumor cell motility, survival, angiogenesis, and proliferation).
Materials and methods
Cell lines and chemicals SKOV-3-luc-D3 cell lines (derived from human ovarian carcinoma cells) purchased from Caliper Life Sciences (Hopkinton, Massachusetts, USA) were used to induce tumor growth. The luciferase reporter, luc-D3, tagged to SKOV-3 cells facilitates noninvasive monitoring of tumor progression and response to BT treatment by luciferase expression. The cells were tested for the absence of mycoplasma before injecting into mice. Pharmaceuticalgrade BT in the form of capsules was obtained from the Centers for Disease Control and Prevention Drug Service (Atlanta, Georgia, USA). The content of the capsule was suspended in injection-grade water (Cat # A12873-02, GIBCO/Life Technologies Corporation, Grand Island, New York, USA) to prepare BT suspensions for administration. Primary antibodies, for example, Ki-67, cleaved caspase-7, and cPARP were purchased from Cell Signaling Technologies (Danvers, Massachusetts, USA). The ATX antibody was purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, California, USA). The TumorTACS In-Situ Apoptosis Detection Kit for TUNEL assay was purchased from Trevigen (Gaithersburg, Maryland, USA).
Animal care
The animal study was approved by the LACUC of Southern Illinois University School of Medicine (Springfield, Illinois, USA). Animals were 4-6-week-old female heterozygous HSD: athymic Nude Foxn1 nu mice purchased from Harlan Laboratories (Indianapolis, Indiana, USA). Mice were housed in static microisolators (up to five mice per cage) and kept under standard conditions: 22 2°C, 45 10% relative humidity, and 12 h light/12 h dark cycle each day, with free access to sterile food and water. All mice were held under specific pathogen-free conditions in an ABLS-2 barrier facility. Mice were subjected to a period of 2 weeks of observation and acclimatization before tumor inoculation.
Mice xenograft study
Fifty, 4-6-week-old HSD: Athymic Nude Foxn1 nu mice, weighing between 22 and 25 g, were inoculated intraperitoneally with 5.0 × 10 6 SKOV-3-luc-D3 cells in Dulbecco's phosphate-buffered saline. Following injection, the animals were imaged twice a week using a noninvasive, in-vivo imaging system (IVIS, Xenogen; Caliper Life Sciences, Mountain View, California, USA) to ensure implantation and to determine the start date for treatment. Regions of interest (ROIs) were established for individual tumors, data were analyzed using the Living Image Software v.3.0 (Xenogen; Caliper Life Sciences), and luminescent signals for these tumors were measured. Mice that showed a marked increase in the luminescence signal over the basal value (day 1 of SKOV-3-Luc-D3 inoculation) were considered to be tumor bearing. Only mice that showed a steady and stable increase in tumor intensity were considered for BT treatment. A time period of 5 weeks was needed for the majority of the mice to show well-established tumor. Mice with similar signal intensities were distributed randomly into five groups of eight animals each (four treatment groups and one control group). As BT capsules are for oral administration, we administered capsular contents as an aqueous suspension through an oral gavage. Each treated group received a different oral dose of BT [30, 60, 120 , or 240 mg/kg body weight (BW)]. Each dose was divided into three doses and administered on days 1, 3, and 5 weekly. The control group received vehicle (injection-grade water) orally on the same schedule. The treatment continued until animals reached standard signs of pain and distress or our predetermined experimental end points (80-100% reduction in tumor). BW, expressed in grams, was used to monitor for systemic toxicity of BT. Mice that reached predetermined end points (either humane or experimental) were killed according to LACUC guidelines. Mice were euthanized in a special euthanasia chamber using carbon dioxide (CO 2 ). Kaplan-Meier survival curves were generated for the time period starting from the first day of BT treatment until the day of the event of interest (either humane or experimental end points). Following killing, blood, ascitic fluid, and tumor tissues were collected. Blood was collected by cardiac puncture in the presence of an anticoagulant (heparin) for ATX measurements. Tumor implants were excised and examined by H&E staining and IHC. The expression of Ki-67 was used to assess the cell proliferation rate, the TUNEL assay was used to assess apoptosis, and changes in ATX levels were compared between the control and the treated groups.
In-vivo bioluminescence imaging
In-vivo bioluminescence imaging (BLI) was performed as described previously [7, 8] using the IVIS Imaging system equipped with a highly sensitive cooled CCD camera. To measure tumor growth in terms of luciferase activity, 150 mg/kg BW of D-luciferin (sodium salt) in sterile 0.9% sodium chloride was injected into the mouse peritoneal cavity 10 min before imaging. Mice were anesthetized using an isoflurane gas anesthesia system. ROIs were established for individual tumors, data were analyzed using the Living Image Software v.3.0, and luminescent signals for these tumors were measured. The signal intensities from manually derived ROIs were obtained and expressed as photon flux (photons/s).
Tumor immunohistochemical and histologic analysis
Tumor tissue from four mice (in each group) was processed for histological analysis and to assess the extent of apoptosis and cell proliferation (Ki-67). Tissue sections, stored at − 80°C, were fixed with a cold fixative (acetone) for 10 min before immunostaining. To assess morphological changes, tissue sections were subjected to routine H&E staining. Cell proliferation was assessed by Ki-67 staining using anti-mouse Ki-67 antibody (1 : 400 dilution) and detected using anti-mouse HRP-DAB Cell and Tissue Staining Kit from R&D Systems Inc. (Minneapolis, Minnesota, USA) according to the manufacturer's instructions. Briefly, acetone-fixed sections were treated with 2% hydrogen peroxide to inactivate endogenous peroxidase and nonspecific binding was blocked by treatment with a blocking reagent. The primary antibody was applied to each section for 1 h at 37°C and the appropriate horseradish peroxidase (HRP)-conjugated secondary antibody was applied at a dilution of 1 : 100 for 1 h at room temperature. Immunoreactivity was subsequently detected using a 3,3′-diaminobenzidine system. Ki-67-positive cells (brown staining) were scored by visual examination of 10 randomly selected microscopic fields.
To assess TUNEL-positive cells, the TumorTACS In-Situ Apoptosis Detection Kit was used. Histologic analysis of DNA fragmentation was used to identify apoptotic cells in sections of the xenograft tumors. During apoptosis, the chromosomal DNA is cleaved by endonucleases to generate DNA fragments with free 3′-hydroxyl residues. In situ, enzyme terminal deoxynucleotidyl transferase (TdT) adds biotinylated nucleotides at the 3′ ends of cleaved DNA fragments. The incorporation of biotinylated nucleotides enables chromosomal DNA fragmentation to be visualized by binding streptavidin-HRP, followed by reaction with 3, 3′-diaminobenzidine to generate a dark brown precipitate. When viewed under a standard light microscope, apoptotic cells are clearly distinguished by the dark brown staining.
Evaluation of BT toxicity
For mice treated with BT, gross measures such as weight loss, distress signs, behavior changes, body condition, and diarrhea, in particular, were investigated for potential signs of BT-related toxicity. A regular record of body condition scoring was maintained. To assess body condition, we used the 'body condition scoring' system as described by Ullman-Culleré and Foltz [9] .
Western blot assays
Western blotting was carried out to analyze the expression of ATX and effectors of apoptosis, such as cleaved caspase-7 and cleaved PARP, using specific antibodies. After resection, tumor tissue was immediately stored at − 80°C until analysis. Tumor tissues from two mice (in each group) were pooled and assessed. The study was repeated with three sets of such pooled tissues for each group. The tissue was homogenized on ice in RIPA buffer containing protease inhibitors, clarified, and subjected to a BCA protein assay, and analyzed by western blotting. The relative levels of protein expression were estimated using the Odyssey imaging software (LI-COR Biotechnology, Lincoln, Nebraska, USA). For tumor tissue, individual proteins were normalized to β-actin loading controls. The ratio of protein to β-actin was normalized to 1 in the control group. For ascites, the amount of protein in each sample was estimated by the BCA assay and an equal amount of protein was loaded from each sample. For assessment of equal protein loading, the gels were stained with Coomassie blue stain. Posttransfer loading was assessed by Ponceau S staining of the immunoblot. ATX expression in the control was considered 1, against which other groups were compared.
Autotaxin assay
ATX activity from plasma and ascites was assessed using colorimetric and western blotting techniques. The phosphodiesterase activity of ATX was measured colorimetrically as described previously [5, 10] . Briefly, 20 μl of plasma/ascites were incubated with 80 μl substrate containing p-nitrophenylphosphonate (pNppp) at a final concentration of 5 mmol/l. The reaction product was measured by reading the absorbance at 410 nm. ATX levels of the vehicle-treated control group were considered 100%, against which BT-treated cells were compared. The data were expressed as %ATX versus control. Ascites and plasma from four mice (in each group) were assessed for ATX activity. Data are shown mean SD of four mice from each group. The assay was repeated twice for each mouse. ATX protein from tumor tissue and ascites was assessed by western blotting as described above.
Statistical analysis
All data are reported as mean SD and statistical significance was defined as P less than 0.05. The Kaplan-Meier method and the log-rank (Mantel-Cox) test were used to compare survival between groups using the statistical analysis SPSS 17.0 software (SPSS Inc., Chicago, Illinois, USA).
Results

Effect of BT on tumor growth
To investigate whether pharmaceutical-grade BT can inhibit the growth of implanted human EOC xenografts in a nude mice model, animals were inoculated with SKOV-3-luc-D3 cells by the intraperitoneal route as described in the Materials and methods section. Representative bioluminescent images (dorsal views) of control and BT-treated mice are shown in Fig. 1 . Only mice that showed detectable tumor with bioluminescence (BLI) values above 1.0 × 10 8 photons/s (∼5 weeks after tumor inoculation) were included in the BT treatment study ( Fig. 2b-f ). Each group received different dosages of pharmaceutical-grade BT, as an aqueous suspension, through an oral gavage. The control group received only vehicle (injection-grade water). Tumor growth was assessed by bioluminescent imaging. The mean tumor growth curves representing each treatment group are shown in Fig. 2 . As shown in Fig. 2a , the mean tumor intensity in the control group increased proportionately with time. A similar increase in tumor intensity was observed with BT-treated groups as well. Our data indicated that pharmaceutical-grade BT did not show antitumor potential at any of the doses tested.
Effect of BT on survival
Kaplan-Meier survival curves were generated for the time period starting from day 1 of BT treatment until the day of the event of interest (either humane or experimental end points). The log-rank (Mantel-Cox) test was used to compare survival curves between groups. As shown in Fig. 3a , BT treatment did not significantly affect survival (P = 0.3677, log-rank). Compared with vehicle-treated mice, the 30 mg/kg BW BT-treated group showed a relatively higher overall survival, but this was not statistically significant. The median survival (after BT treatment) for the 30 mg/kg BW group was 45 days, whereas the vehicle-treated control group survived 35 days. The median survival times for the 60, 120, and 240 mg/kg BW groups were 42, 39, and 32 days, respectively.
BT toxicity
To assess general health, mice were regularly monitored for appearance, activity (natural vs. induced), and body condition. For mice treated with BT, gross measures such as weight loss, clinical signs of illness, behavior changes, and diarrhea, in particular, were investigated for potential signs of BT-related toxicities/side effects. A regular record of body condition was maintained. None of the mice treated at any BT dose showed signs of morbidity. BWs were not affected by BT treatment (Fig. 3b ). None of the mice showed abdominal distension until just before euthanasia. No difference was observed between vehicle-treated and BT-treated mice in any of the clinical signs of illness.
Effect of BT on tumor histology
To investigate the effect of BT on the histology of EOC xenografts, tumor tissue was processed for morphological studies (H&E staining). SKOV-3 cells are a wellcharacterized platinum-resistant phenotype of serous ovarian cancer [11] . As shown in Fig. 4 , most of the tumors show poorly differentiated serous cystadenocarcinomas with variable nuclear sizes. Tumor implants from vehicle controls were composed primarily of ovarian epithelial cancer cells with cobblestone-like characteristics and were relatively uniform epithelial cells with irregular and hyperchromatic nuclei. A similar morphology was observed with mice treated with higher doses of BT, for example, 120 and 240 mg/kg BW. In contrast, mice treated with BT at 30 mg/kg BW showed a slightly increased proportion of noncellular stromal components with pleomorphic and hyperchromatic nuclei.
Inhibition of cell proliferation in vivo
We performed Ki-67 IHC to investigate the effect of BT on cell proliferation. Ki-67 was used as a surrogate marker of tumor aggressiveness, with dark brown nuclear staining considered as positivity for Ki-67 ( Fig. 5 ). On the basis of the scoring of 10 randomly selected microscopic fields, the extent of proliferation was expressed as the proliferative index (percentage of Ki-67-positive cells). Data were expressed as mean SD of four mice from each group. As shown in Fig. 5 (bar graph) , the proliferation index was significantly higher in the vehicletreated tumors compared with the 30 mg/kg BW BT group (51.33 6.11% vs. 34.33 3.21, respectively, P < 0.05, Student t-test). Our results suggest that the delayed tumor growth observed at the 30 mg/kg BW dose initially may have been caused by a reduction in the proliferative index of tumors on the basis of Ki-67 staining. However, no significant difference was observed between control and all other treatment doses. The proliferative index was 51. 33 
Induction of apoptosis in vivo
The extent of apoptosis in tumor tissue was determined by DNA fragmentation (TUNEL) and the expression of apoptotic effectors such as cleaved caspase-7 and cleaved PARP. Apoptotic cells with condensed and irregularly shaped nuclei stain positively for TUNEL (dark brown). On the basis of the scoring of 10 randomly selected microscopic fields, the apoptotic index (the percentage of brown-stained apoptotic cells) was calculated for each group. Data were expressed as mean SD of four mice from each group. The TUNEL assay showed an increase in apoptotic-positive cells in all the BT-treated groups compared with the vehicle-treated group (Fig. 6 ). The apoptotic index increased from 8 1% in vehicle-treated (controls) to 41 5.29% in the 30 mg/kg BW group ( Fig. 6; bar graph) . The apoptotic index was 28.33 4.51, 28.67 5.03, and 29.33 2.08% in the 60, 120, and 240 mg/kg BW groups, respectively, which was statistically significant compared with the vehicle-treated control group (8 1%, P < 0.01 for all groups). The observation of apoptosis in BT-treated tumor tissue was also confirmed by the expression of cleaved caspase-7 and cleaved PARP using western blotting. The cleavage of PARP and procaspase 7 is a well-documented indicator of apoptosis [12, 13] . As shown in Fig. 7a , enhanced expression of cleaved caspase-7 and cleaved PARP was observed in BT-treated tumors compared with vehicletreated tumors. Very weak expression was observed in vehicle-treated tumor tissue. Our results indicate the apoptosis-inducing potential of BT.
Effect of BT treatment on ATX inhibition
ATX activity was estimated in plasma, ascites, and tumor tissue using colorimetric and western blotting techniques. All methods showed similar trends. Ascites and plasma from four mice (in each group) were assessed for ATX activity using the colorimetric method. Data were shown as mean SD of four mice from each group. ATX levels in the vehicle-treated control group were considered 100%, against which all treated groups were compared. As shown in Fig. 7b , statistically significant differences in ATX levels were not observed between BT-treated and BT-untreated groups in plasma and ascites. High intragroup variations in ATX levels were observed in plasma and ascites.
ATX expression in ascites was also assessed by western blotting. For ascites, ATX expression in the BT-treated groups was normalized to ATX expression in the control (which was considered equal to 1). As shown in Fig. 7c and d (densitometry analysis), no significant difference was observed between BT-treated and BTuntreated mice.
In the case of tumor tissue, ATX expression was assessed by western blotting (Fig. 7a ). The ratio of protein to actin was normalized to 1 in the control group. As shown in Fig. 7d , the relative level of ATX expression, as assessed by densitometry, was not statistically different between the treatment groups and vehicle. Because of the high intragroup variability of ATX levels in plasma and ascites, it is difficult to make meaningful conclusions on the effect of BT on ATX and further studies using a greater number of animals will be needed to elucidate the role of ATX.
Discussion
Major hurdles associated with the treatment of ovarian cancer include chemoresistance and toxicity of standard drugs [14, 15] . It is essential to develop novel strategies to overcome resistance and to improve the long-term survival of ovarian cancer patients. 'Drug repurposing' is a cost-effective alternative to new drug discovery. In this study, we focused on pharmaceutical-grade Bithionol [2,2′-sulfanediylbis(4,6-dichlorophenol)], BT, a clinically approved antiparasitic drug repurposed as a potential antiovarian cancer drug.
BT was shown to be an effective anticancer agent in preclinical models representing breast cancer, melanoma, ovarian, and cervical cancer [5, [16] [17] [18] . In our recent in-vitro study, we showed the ability of BT [chemical grade from Sigma-Aldrich (St. Louis, Missouri, USA)] to exert cytotoxic effects on a panel of ovarian cancer cell lines irrespective of their cisplatin sensitivities. BT was shown to induce cell death by apoptosis and the mechanism(s) of action were shown to be through cellcycle regulation, ROS generation, NF-kB inhibition, and ATX inhibition [5] . In view of these in-vitro observations, the major objective of the present study was to assess whether BT (pharmaceutical grade) is capable of inhibiting the growth of implanted human EOC xenografts in a nude mouse model and to understand its mechanisms(s) of action in vivo.
In the present study, we established an ovarian cancer xenograft model by an intraperitoneal injection of SKOV-3-luc-D3 human EOC cells into nude mice. Tumor growth and treatment response were studied using BLI. SKOV-3 cell lines were selected as they are known to produce aggressive intraperitoneal disease with carcinomatosis and ascites that resemble human ovarian cancer in many aspects. Furthermore, our in-vitro data showed the susceptibility of SKOV-3 cells to cytotoxic effects of BT. BT was shown to cause cell death by caspases-mediated apoptosis in SKOV-3 cells and the mechanism(s) of action were shown to be through cell-cycle arrest, ROS generation, and inhibition of ATX [5] . Our in-vitro data support the significance of SKOV-3 xenografts as an experimental model of EOC apoptosis and offer an attractive paradigm to study the mechanisms of action of drugs.
In this work, we administered BT capsular contents as an aqueous suspension through an oral gavage. We tested a wide range of BT doses from 30 to 240 mg/kg BW. The dose range selected was based on our in-vitro BT cytotoxicity data and also on the published data on toxicity, metabolism, clearance kinetics, and oral LD 50 of BT in animals and humans. Furthermore, we took into account a previously published study that showed growth inhibition of breast cancer xenografts tumors when treated Copyright r 2016 Wolters Kluwer Health, Inc. All rights reserved. with BT at 60 mg/kg BW [16] . Our in-vitro results showed the cytotoxic effects of BT toward all the ovarian cancer cell lines tested. SKOV-3-luc-D3 cell lines purchased from Caliper Life Sciences have shown BT IC 50 values of 51 6 and 31 4 μmol/l at 48 and 72 h after BT treatment, respectively. Although pharmacokinetics varies from one species to another, several published studies reported that oral administration of 50 mg/kg BT divided into three alternate daily doses for 5 days will maintain serum levels of BT in the range of 140-550 μmol/l in rabbits, dogs, and humans [16, 17, [19] [20] [21] [22] .
With respect to treatment duration, we followed a similar treatment regimen usually prescribed for humans when treating parasitic infections. In humans, the therapeutic doses are administered orally on alternate days, usually in two or three divided doses. In the present study, each treated group received a different dose of BT orally (30, 60 , 120, or 240 mg/kg BW). Each dose was administered (in three divided doses) on days 1, 3, and 5 of each week. In our study, the treatment continued until animals reached humane (signs of pain and distress) or experimental end points (80-100% reduction in tumor). The treatment duration was also selected on the basis of the reports of lack of BT accumulation in many species (humans, dogs, rabbits). In humans, accumulation of BT was not observed even after 10 oral doses of 50 mg/kg administered on alternate days [16, [20] [21] [22] . It may be essential to maintain a certain concentration of the drug to prevent repopulation of tumor cells. In fact, tumor repopulation between cycles of chemotherapy likely has a negative effect on clinical outcome in ovarian cancer patients [23, 24] . In view of these facts, we treated the mice continuously with BT. In the absence of toxicity, the treatment continued until the specified end point had been reached (either humane or experimental).
In the present study, pharmaceutical-grade BT did not show significant antitumor potential at any of the doses tested. Zhai et al. [25] reported the antitumor activity of BT as a single drug in a human ovarian cancer xenograft mouse model. In another study, growth inhibition of breast cancer xenograft tumors was observed when treated with BT-cyclodextrin at 60 mg/kg BW [16] . The reasons for the lack of a therapeutic effect of BT in our study may be because of (i) the use of pharmaceuticalgrade BT, (ii) administration as an aqueous suspension, and/or (iii) disease stage at which treatment started. In the present study, the contents of the BT capsules were administered as a homogenous aqueous suspension through an oral gavage. Although we do not have the pharmacokinetic data to interpret our results, the generally observed poor water solubility and subsequent poor absorption of BT may explain our findings. The aqueous solubility is a major indicator for the solubility in intestinal fluids and its potential contribution toward bioavailability issues. In addition to solubility, the stage of the disease at which treatment started may also influence the outcome. To mimic human disease at the detection stage, we delayed the treatment until 5 weeks after tumor inoculation to have a strong tumor signal. A future study, with an early BT intervention, could help us draw a bigger picture of the potential of BT as an antitumor drug as well as its mechanism of action.
In our previous in-vitro study, BT (chemical grade) induced cell death through apoptosis and by affecting cell-cycle regulation, ROS generation, NF-kB inhibition, and ATX inhibition [5] . We investigated whether pharmaceutical-grade BT can induce similar effects in in vivo as well. In the present study, we investigated the effect of BT treatments on cellular proliferation, apoptosis, and ATX levels in an intraperitoneal xenograft It is well known that damaged apoptotic pathways are hallmarks of cancer cells and an important cause of resistance to cytotoxic agents [26] . The ability to induce apoptosis is a critical factor for any effective treatment against cancer [27] . Our previous in-vitro study showed the inhibitory effect of BT (chemical grade) on ovarian cancer cell growth by induction of caspase-3/7 activity, DNA fragmentation, and loss of mitochondrial potential. The present study confirms the proapoptotic role of BT (pharmaceutical grade) in vivo as shown by increased expression of apoptotic markers, cleaved caspase-7, and cleaved PARP, and by increased nuclear fragmentation (TUNEL assay). A significant increase in apoptosis was observed in all BT-treated groups compared with vehicle. It is unclear why we observed minimal tumor inhibition despite enhanced apoptosis. The ability of BT to induce apoptosis is encouraging.
It is understood that one of the mechanisms by which BT inhibits tumor growth is by inhibition of ATX enzyme activity or secretion. ATX is known to increase the aggressiveness and invasiveness of transformed cells, and directly correlates with tumor stage and grade in several human malignancies, including ovarian cancer [28, 29] . Tumors with increased ATX expression include breast cancer [30] , teratocarcinoma [31] , neuroblastoma [32] , glioblastoma [33] , lung carcinoma [34] , thyroid carcinoma [35] , and ovarian cancer [28, 29, 36] . Currently, there are no small-molecule inhibitors of ATX on the market or in the clinic. It is essential to identify putative ATX inhibitors that reduce tumor metastasis and tumor growth both in vitro and in vivo. In this context, further exploration of BT as an ATX inhibitor is highly desirable. Previously, BT was shown to inhibit solid tumor growth in several preclinical cancer models by targeting ATX [5, 17, 37] . In our recent in-vitro study, we also reported inhibition of ATX in BT (chemical grade)-treated ovarian cancer cell lines [5] . Zhai et al. [25] , proposed inhibition of ATX enzyme activity and ATX secretion as one of the mechanisms by which BT inhibits tumor growth in a human ovarian cancer xenograft mouse model. Given the significance of ATX in ovarian cancer [38] [39] [40] [41] , we studied the effect of BT on ATX in vivo using an EOC intraperitoneal xenograft model. In this present study, no significant differences in ATX levels were observed in tumor tissue, ascites, and plasma from BT-treated mice versus BT-untreated mice. Because of the high variability observed within each group, it is difficult to come to any meaningful conclusions on the effect of BT on ATX. Further work using a greater sample size will be necessary to confirm the role of ATX.
Although our study did not show the antitumor potential of pharmaceutical-grade BT in vivo, the ability of BT to induce apoptosis still makes it a promising therapeutic agent. In addition, the lack of toxicity at any of the tested doses and delayed tumor growth observed at lower doses are important features shown in our present study. These characteristics are worth exploring further in future optimization studies. To improve bioavailability and antitumor response, our future studies would also focus on pharmacokinetic data using different BT formulations (chemical vs. pharmaceutical grade), different vehicles, different routes of delivery, and wide dose ranges. If not effective as a single agent, it can also be tested in combination with other standard chemo drugs for its ability to sensitize the cells to chemotherapy. However, this is the first preliminary in-vivo antitumor efficacy study using pharmaceutical-grade BT.
Conclusion
Keeping in view the concept of 'drug repurposing', we evaluated the antitumor potential of pharmaceuticalgrade BT using an ovarian cancer xenograft model. No significant antitumor activity was observed at any of the doses tested. However, the ability of BT to induce apoptosis still makes it a promising therapeutic agent. Further confirmatory and optimization studies are essential to enhance the therapeutic effects of BT.
